HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed) | PAR 25 154

Opportunity Information: Apply for PAR 25 154

The NIH HEAL Initiative funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)" (Funding Opportunity Number PAR-25-154) supports small, early-stage pilot projects aimed at uncovering new, druggable biological targets for pain. The core goal is to jumpstart research on proteins that are considered part of the "understudied druggable proteome," meaning proteins that are potentially amenable to therapeutic targeting but have not yet been well characterized or widely investigated. Projects are expected to focus specifically on eligible understudied proteins identified in the NOFO and to produce the kind of preliminary evidence and practical research tools that would make these proteins more viable as future pain-treatment targets.

This program is designed for basic biochemical and biological work rather than later-stage translational or clinical testing. The R03 mechanism is intended to fund tightly scoped projects that can quickly generate foundational data, such as initial validation that a given protein influences pain-related biology, early evidence of target engagement, basic functional characterization, pathway or mechanism clues, development of assays, reagents, or other enabling tools, and other early discoveries that reduce uncertainty and set up larger studies. Because it is explicitly "Clinical Trial Not Allowed," applications should not propose clinical trials or work that meets NIH's definition of a clinical trial. The emphasis is on building the early evidence base needed to justify and accelerate future therapeutic development efforts.

The opportunity sits within the broader NIH Helping to End Addiction Long Term (HEAL) Initiative. While the immediate scientific focus here is pain and pain management through identification of new drug targets, the larger HEAL context is about accelerating the development of safer, more effective medications that can reduce reliance on opioids and address multiple parts of the opioid addiction cycle. That includes preventing progression to chronic opioid use and tackling withdrawal, craving, relapse, and overdose. In practical terms, this NOFO is part of a pipeline approach: by expanding the universe of credible, druggable pain targets, it aims to support new non-opioid (or opioid-sparing) therapeutic strategies that could ultimately reduce opioid exposure and its downstream harms.

The award ceiling listed is $100,000, consistent with the small-scale, pilot nature of R03 grants. The NOFO is categorized as a discretionary grant program within health-related activity areas (CFDA numbers listed include 93.121, 93.213, 93.273, 93.279, 93.350, 93.846, 93.853, 93.865, and 93.866). The original closing date provided is 2026-07-16, and the posting creation date is 2024-12-11, which together indicate a multi-year window in which NIH expects to receive and review applications according to the schedule and instructions in the full announcement.

Eligibility is broad and spans many organization types. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations both with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; public housing authorities and Indian housing authorities; federally recognized Native American tribal governments; and Native American tribal organizations other than federally recognized tribal governments. The NOFO also highlights several categories of "other eligible applicants," including Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, historically Black colleges and universities, tribally controlled colleges and universities, eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.

At the same time, there are clear limits related to foreign participation. Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined in the NIH Grants Policy Statement, meaning a U.S.-based applicant may be able to include certain foreign collaborations or elements if they meet NIH policy requirements and are justified within the project.

Overall, this NOFO is best viewed as an entry point for investigators who have compelling ideas about unexplored or lightly explored druggable proteins and can use modest, targeted funding to generate the first tranche of evidence and tools needed to validate those proteins as pain-relevant targets. The intended outcome is not a finished therapy, but a credible early-stage package of data and research capabilities that makes subsequent larger-scale mechanistic studies and drug discovery efforts more feasible and competitive within the HEAL-aligned push for better pain treatments and reduced opioid-related harm.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.273, 93.279, 93.350, 93.846, 93.853, 93.865, 93.866.
• This funding opportunity was created on 2024-12-11.
• Applicants must submit their applications by 2026-07-16. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $100,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 25 154

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: